Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants

Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT).

To prevent recurrence of invasive fungal infection in patients with allogeneic stem cell transplants

Inclusion Criteria:

• Patients with proven or probable IFI in previous 12 months receiving an allogenic stem cell transplant for any haematological disease

Exclusion Criteria:

• Pregnant or lactating women
• Severe disease other tham the underlying condition
• Active, symptomatic uncontrolled Invasive Fungal Infection
• Any evidence of active fungal disease as defined by MSG-EORTC criteria
• Concomitant use of Voriconazole 36 hours before chemotherapy until 48 hours after chemotherapy
• Other medical conditions, including HIV positive serology that would interfere with the evaluation of therapeutic response or safety of study drug